1. Introduction {#s0005}
===============

Wolfram syndrome (WS) was first described in 1938 by Wolfram and Wagener as a rare progressive neurodegenerative disorder with an autosomal recessive pattern of inheritance ([@bb0150]). WS is also known by the acronym DIDMOAD given that it is characterized by the presentation of multisystem symptoms: diabetes insipidus (DI), type I diabetes mellitus (DM), optic atrophy (OA), and deafness (D) ([@bb0025]). Other clinical symptoms were found to be associated with WS including ataxia, peripheral neuropathy, psychiatric problems, and renal tract abnormalities ([@bb0060]). WS is diagnosed early in life with a juvenile onset of DM and OA ([@bb0070]); patients die young at a median age of 30 years mostly due to respiratory failure caused by brainstem atrophy ([@bb0100]). WS prevalence is estimated to be 1 in 770,000 with a carrier frequency of 1 in 354 ([@bb0090]). Inoune and colleagues identified the gene responsible for Wolfram syndrome as *WFS1* ([@bb0080]). *WFS1* gene is located within the short arm of chromosome 4 (4p16.1), spanning about 33.4 kb of DNA and composed of eight exons, where exon 1 is noncoding, exon 2 is the start point of translation, and exon 8 is the largest exon encompassing 2.6 kb of DNA ([@bb0115]). *WFS1* gene codes for the wolframin protein; an 890 amino acid with an estimated molecular mass of 100 kDa ([@bb0070]). Wolframin is an endoglycosidase H-sensitive integral membrane glycoprotein with nine hydrophobic transmembrane domains and large hydrophilic regions at the N- and C-termini ([@bb0050]).

Wolframin is expressed in in the β-cells of pancreas, heart, brain, muscle tissues, liver, spleen and kidney ([@bb0075]). Wolframin is an endoplasmic reticulum (ER)-localized protein and studies indicate a role in protein synthesis, protein folding and modification, membrane trafficking, and ER stress signaling ([@bb0100]). Additionally, studies have shown that wolframin protein has a calmodulin (CaM) binding site at the N-terminal cytoplasmic domain between the residues Glu90 and Trp186 ([@bb0155]), suggesting a role for wolframin in maintaining the intracellular homeostasis of calcium ions by controlling their levels in the ER ([@bb0110]). Most WS patients have a mutation(s) in the WFS1 gene and \> 230 mutations in the gene have been identified so far ([@bb0110]). Accordingly, these mutations were found to be mostly distributed in exon 8 and they include missense, nonsense, splicing mutations, frameshift insertions, and frameshift deletions, with homozygous and compound heterozygous genotypes ([@bb0030]). Most of the mutations found in WS patients result in the expression of a loss of function wolframin; however, the specific role of the mutated wolframin in the expression of WS symptoms and the exact genotype-phenotype relationship in WS patients are not clear yet ([@bb0025]).

Interestingly, it was reported that WS patients show some level of phenotypic heterogeneity where certain patients did not develop diabetes insipidus but they demonstrated certain features as upper gastrointestinal ulceration with bleeding tendency ([@bb0055]). A Jordanian group studied the possibility of locus heterogeneity and the presence of mutations in other genes that might be associated with expressing different symptoms in WS patients. Linkage analysis in Jordanian WS patients who developed different symptoms resulted in identifying another locus associated with the disease at chromosome 4q22-25 ([@bb0125]). Amr et al. identified a zinc-finger gene, *ZCD2/WFS2*, in this region and were able to show that three consanguineous Jordanian families with WS harbor mutations in this gene resulting in a different clinical manifestation of WS such as patients show no signs of diabetes insipidus or hearing loss however, patients show upper gastrointestinal ulceration with bleeding tendency ([@bb0010]).

In this study, we investigated the molecular status of *WFS1* gene in two unrelated Jordanian families, including five WS patients, to identify mutations associated with the disease which will be pivotal in genetic screening for parental counseling prior to conception and aid in early diagnosis of the disease.

2. Methods {#s0010}
==========

2.1. Patients {#s0015}
-------------

Five patients (4 females and 1 male) from two unrelated families from northern Jordan were recruited in this study. The minimal criteria to diagnose WS were early onset diabetes mellitus and optic atrophy. Clinical records of the selected patients were retrieved from the files of Jordanian Royal medical services (JRMS). All study subjects underwent comprehensive clinical examination including ophthalmological, endocrinological, audiographic, urological, and neurological evaluations. Blood was collected from all patients as well as their parents, siblings, 39 close family members, and 100 control volunteers (unrelated) in EDTA tubes under aseptic conditions and stored at 4 °C. Written consent was obtained from subjects participating in this study and the research was approved by the human research ethics committee of the Jordan University of science and technology. The main clinical features of the patients are listed in [Table 1](#t0005){ref-type="table"}.

2.2. DNA extraction {#s0020}
-------------------

Genomic DNA was extracted from whole blood using GeneJET Genomic DNA Purification Kit (Thermo Scientific) according to the manufacture\'s recommendations. Nanodrop (ND-1000) was used to check the concentration (\> 50 ng/μL) and purity (against RNA and protein) of the isolated DNA.

2.3. Mutational analysis {#s0025}
------------------------

Mutational screening was done on the coding region of *WFS1* gene of exons 2--8 by PCR and direct sequencing. Primers used to amplify these exons were previously described ([@bb0040]). PCR reactions were performed in a final volume of 30 μL containing 100 ng (2--4 μL) genomic DNA, 15 μL master mix (GoTaq® Green Master Mix, Promega, USA), 1--2 μL of 5 pmol of forward and reverse primers, and nuclease free water was added to a final volume of 30 μL. PCR conditions were performed as follows: an initial denaturation at 95 °C for 7 min, followed by 30 cycles of denaturation step at 95 °C for 1 min, annealing step for 30 s, and extension step at 72 °C for 30 s, then a final extension step at 72 °C for 7 min. PCR products were visualized by gel electrophoresis with ethidium bromide dye. The purified PCR products were sequenced using the big dye terminator cycle sequencing reaction kit and analyzed on an ABI prism 3100 Genetic Analyzer (Applied Biosystem, USA). Mutational analysis was carried out using mutation surveyor software (SoftGenetics, PA, USA). Validity of variations in the results was done by sequencing both DNA strands of two independent PCR products.

3. Results {#s0030}
==========

3.1. Patients and clinical data {#s0035}
-------------------------------

Five patients from two unrelated families were studied. Pedigrees of the families are shown in [Fig. 1](#f0005){ref-type="fig"} and the main clinical features of the patients are shown in [Table 1](#t0005){ref-type="table"}. The first family ([Fig. 1](#f0005){ref-type="fig"}a) consists of three WS patients, as three of seven siblings fulfilled the minimal diagnostic criteria. Diabetes mellitus was diagnosed in the first decade of life, patients received insulin with poor compliance to treatment. Ophthalmological examination revealed optic atrophy at a mean age of 12.4 ± 2.05 (range 10--15) and a recent eye examination showed visual acuity \< 6/60 in both eyes. All patients were subjected to audiography with abnormal results in all cases. Analyses of urine and serum osmolarity confirmed the diagnosis of diabetes insipidus. Urinary tract abnormalities were observed in all patients. Furthermore, all patients showed neurological abnormalities, while two of them (patient IV-18 and patient IV-22) were diagnosed with epilepsy. The second family ([Fig. 1](#f0005){ref-type="fig"}b) had four siblings with two of them diagnosed as WS patients. They were known as diabetic case since the age of three. On fundoscopic examination, bilateral optic atrophy without diabetic retinopathy was confirmed at the age of five. Urinary tract abnormalities were observed in the two patients and ultrasonography examination diagnosed patient II-1 with hydronephrosis and gall bladder stones. Audiometric studies showed bilateral high frequency sensorineural hearing loss by the age of five. According to neurological evaluation, the patients had poor concentration and moderate intellectual disability.

3.2. Mutation analysis data {#s0040}
---------------------------

Two unrelated families with five WS patients were examined in this study. Direct sequencing of exons 2--8 of *WSF1* gene revealed several genetic variations including deletion mutations, nonsense mutations, and several polymorphisms in both families ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Two deletion mutations were detected in family 1, V415del and F247fs ([Table 2](#t0010){ref-type="table"}). The V415del mutation was identified in three patients and in three healthy family members, father, brother, and uncle, as they were all heterozygous for this mutation ([Fig. 1](#f0005){ref-type="fig"}a). The V415del mutation is a three nucleotide deletion located in exon 8 causing valine to be missed in the third transmembrane domain of the protein. The V415del mutation was previously reported in several studies and it is thought to result in the degradation of the wolframin protein ([@bb0045]). Moreover, F247fs mutation was identified in three patients and in four healthy family members, mother, sister, first uncle and a cousin; likewise, they were all found to be heterozygous for this deletion mutation ([Fig. 1](#f0005){ref-type="fig"}a). The F247fs is located in exon 7, and it causes a deletion of two T nucleotides that results in a frame shift at F247 and losing \~ 72% of wolframin in the new frame. This mutation is also reported to be associated with WS ([@bb0120]). Interestingly, patients IV-18, IV-19, and IV-22 were compound heterozygous for these two deletion mutations (V415del and F247fs). Additionally, six single nucleotide polymorphisms (SNPs) were identified in the exon 8 region in both families ([Table 3](#t0015){ref-type="table"}). One of the SNPs is non-synonymous polymorphism I333V (rs1801212) which was detected as a heterozygous polymorphism in patients of family 1 and as a homozygous polymorphism in patients of family 2; furthermore, allelic frequency for this SNP was calculated and it was found to be 83% in the Jordanian population. This SNP was previously reported in Iranian families ([@bb0140]). Regarding the other five SNPs detected, they were shown to have no effect on changing the amino acid sequence but two of them (c.1023T \> C, and c.2565A \> G) were reported to be associated with other disorders ([Table 3](#t0015){ref-type="table"}).

3.3. Novel nonsense mutation in *WSF1* gene {#s0045}
-------------------------------------------

Mutational analysis of exon 5 resulted in the identification of a novel nonsense mutation in members of family 2 ([Fig. 2](#f0010){ref-type="fig"}a). This novel mutation c.55G \> A, p.W185X was found to be homozygous in the two patients II-1 and II-2 and heterozygous in both parents and two healthy siblings ([Fig. 1](#f0005){ref-type="fig"}b). The W185X mutation is located in exon 5 of the cytoplasmic domain of the wolframin protein ([Fig. 2](#f0010){ref-type="fig"}b). The substitution of tryptophan to a stop codon results in a truncated protein that is 185 amino acids long, thus only 20.7% of wolframin is translated with only more than the half of the N-terminal of the protein. This novel mutation was not detected in the 100 healthy control samples or in the healthy and affected members of family 2 ([Fig. 1](#f0005){ref-type="fig"}a). Additionally, this novel mutation is within an evolutionary conserved region of wolframin ([Fig. 3](#f0015){ref-type="fig"}).

4. Discussion {#s0050}
=============

Wolfram syndrome is a rare autosomal recessive neurodegenerative disorder, characterized by the manifestation of multisystem symptoms at an early age of life ([@bb0025]). Several studies have previously described the linkage of this syndrome to certain markers at chromosome 4p16.1 and specifically the gene *WFS1* was identified as the causative agent in the pathophysiology of Wolfram syndrome ([@bb0105], [@bb0020], [@bb0035]). A wide spectrum of mutations in the *WFS1* gene have been identified in WS patients ([@bb0145], [@bb0070], [@bb0005], [@bb0110]). In this study, we have conducted a mutational screening of *WFS1* gene in five WS patients from two unrelated Jordanian families and we report a detailed mutational and clinical observations of these patients. In this study, WS patients developed diabetes mellitus at their first decade of life with a median age of 3 years, followed by developing optic atrophy at a median age of 10 years, these observations are consistent with WS clinical characteristics reported in previous studies ([@bb0115], [@bb0005], [@bb0060]). Interestingly, all of the five patients selected in this study have developed diabetes insipidus early in their life with a median age of 4 years, which is completely discordant with previous studies as diabetes insipidus is usually expressed later; at their second decade of life ([@bb0070], [@bb0065], [@bb0055]). Moreover, urological evaluation illustrated that all WS patients included in this study demonstrated urinary tract abnormalities. Previous studies showed clinical heterogeneity regarding urological abnormalities, as some studies described 100% prevalence among WS patients ([@bb0130], [@bb0055]) while other studies showed lower frequencies of urinary tract abnormalities ([@bb0015], [@bb0085]). Urinary tract abnormalities and high output of urine are associated with the development of diabetes mellitus and diabetes insipidus which contribute to renal tract dilation ([@bb0095]). Additionally, all the selected patients showed audiographic defects and neurological deterioration which is consistent with previous studies ([@bb0070], [@bb0055], [@bb0025]).

Three different molecular variations and six polymorphisms were identified in the WS patients studied including in-frame deletion, frameshift deletion, and a novel nonsense mutation. The first family was compound heterozygous for two deletion mutations (V415del and F247fs\*3) in exon 8 and exon 7. In the second family, we identified a novel nonsense mutation c.55G \> A, p.W185X in exon 5 with a recessive pattern of inheritance. The identified mutations were distributed between exons 5--8, which is in contrast to other studies where most of the reported mutation were concentrated in exon 8 ([@bb0065], [@bb0055], [@bb0025]).

Two deletions were identified in the present study namely, V415del and F247fs were reported previously ([@bb0070], [@bb0120]) however, this is the first report to demonstrate their occurrence together in a compound heterozygous manner in the same patient. The mutation V415del is located in exon 8 and it results in the deletion of the amino acid valine positioned in the third transmembrane domain; this in-frame deletion is considered as a partial loss of function kind of mutation and it is thought to have an effect on the localization of wolframin protein to the ER membrane ([@bb0070], [@bb0135], [@bb0065], [@bb0055], [@bb0115], [@bb0030], [@bb0120], [@bb0045]). The F247fs mutation is located in exon 7 within the cytoplasmic domain at the N-terminus, and it results in the deletion of two T nucleotides that causes a frameshift in the codons sequence resulting in an \~ 72% loss of wolframin amino acid sequence including most of the TM domain and the C-terminus domain thus, it is categorized as a complete loss of function mutation as no functional wolframin protein is expressed in this case ([@bb0120]).

We also report the identification of a novel homozygous nonsense mutation within exon 5 (W185X) in two patients of family 2. This mutation is likely to be pathogenic and associated with the pathophysiology of WS, as it was found to be homozygous only in patients whereas in healthy parents and siblings it is heterozygous; additionally, the W185X mutation was not found in 100 healthy control samples and it is positioned within an evolutionary conserved region of wolframin. This mutation can be considered as a loss of function mutation since the resulting truncated protein lost both the transmembrane domain and the C-terminal domain. Additionally, the W185X mutation lies within the CaM binding domain in wolframin protein which is thought to have a role in the regulation of wolframin function in response to calcium levels. It was demonstrated in a previous study that truncation and deletion mutations at the CaM binding domain in wolframin protein can completely abolish its function and three mutations (Ala127Thr, Ala134Thr, and Arg178Pro) located from Glu90 to Trp186 were identified that completely eliminated the CaM binding ability of wolframin; furthermore, these mutations were associated with WS which indicates that impairment of CaM binding ability can interfere with wolframin function resulting in developing a WS ([@bb0155]).

In summary, the aim of this study was to identify *WFS1* mutations associated with WS in two, newly recognized, unrelated Families from Jordan and to determine the genotype-phenotype correlations. Future studies will be directed toward elucidating the functional significance of the identified mutations on wolframin function.

This work was funded by the deanship of research of the Jordan University of Science and Technology (grant number 20140279). We would like to express our gratitude to the two families who participated in this study.

![Pedigree of the WFS families. (a) family 1 and (b) family 2. wolfram syndrome: ![](fx1.gif). c.1243_1245 del mutant allele: ![](fx2.gif). C.740_741 mutant allele: ![](fx3.gif). c.554G \> A mutant allele: ![](fx4.gif).](gr1){#f0005}

![The novel mutation p.W185X (A) demonstrated a homozygous c.554G \> A mutation, predicting a Tryptophan to stop codon nonsense substitution at protein residue 185 (p.W185X). (B) Hypothetical structure of the wolframin protein, and position of the novel mutation p.W185X indicated by red circle.](gr2){#f0010}

![Multiple sequence alignment of the WFS1 protein region flanking residues trp185. ClustalW analysis demonstrates that tryptophan 185 is well conserved in orthologs. Nonsense mutation is indicated by arrow.](gr3){#f0015}

###### 

Clinical feature of the WFS patients.

Table 1

  Family   Patient   Gender   Age   DM (age at diagnosis)   OA (age at diagnosis)   DI (age at diagnosis)   Deafness (age at diagnosis)   Urinary tract abnormalities   Neurological abnormalities   Other complication
  -------- --------- -------- ----- ----------------------- ----------------------- ----------------------- ----------------------------- ----------------------------- ---------------------------- ------------------------------------------
  F1       IV-18     Female   20    3                       15                      4                       15                            \+                            \+                           Epilepsy
  F1       IV-19     Female   17    5                       12                      5                       12                            \+                            \+                           −
  F1       IV-22     Female   11    4                       10                      4                       9                             \+                            \+                           Epilepsy
  F2       II-1      Female   19    3                       5                       4                       5                             \+                            \+                           Hydromephrosis Remove gall bladder stone
  F2       II-2      Male     15    3                       5                       4                       5                             \+                            \+                           −

DM, diabetes mellitus; DI, diabetes insipidus; OA, optic atrophy. All Ages in years. (+) denotes complication present. (−) denotes complication absent.

###### 

Mutations detected in *WFS1* gene of both families.

Table 2

  Family   Patients   Exon           Nucleotide change   Amino-acid change   Type of mutation   Protein domain          Zygosity                Reference
  -------- ---------- -------------- ------------------- ------------------- ------------------ ----------------------- ----------------------- -----------------
  FI       IV-18      Ex-8           c.1243_1245del      p.Val415del         Deletion           TM3                     Compound heterozygote   2,5,11,15,17,18
  IV-19                                                                                                                                         
  IV-19                                                                                                                                         
           Ex-7       c.740_741del   p.Phe247Cysfs\*3    Deletion            CD1                Compound heterozygote   11                      
  F2       II-1       EX-5           c.554G \> A         p.W185X             Nonsense           CD1                     Homozygote              This study
  II-2                c.554G \> A    p.W185X                                                                                                    

TM-transmembrane domain with α-helix; CD-cytoplasmatic domain. Reference sequence AF084481.

###### 

SNPs in *WFS1* gene of both families.

Table 3

  SNP          Exon   Details        Amino acid changed   Patients   Associated with disorder                  
  ------------ ------ -------------- -------------------- ---------- -------------------------- ---- ---- ---- -------------------------------------------------------------
  rs1801212    8      c.997A \> G    I333V                GA         GA                         GA   AA   AA   Not associated with any disorder
  rs56072215   8      c.1023T \> C   F341F                TC         TC                         TC   TT   TT   Major depressive disorder
  rs2230719    8      c.1725C \> T   A575A                CT         CT                         CT   TT   TT   Not associated with any disorder
  rs6173501    8      c.2124C \> T   R708R                CT         CT                         CT   TT   TT   Not associated with any disorder
  rs230721     8      c.2322G \> A   K774K                GA         GA                         GA   AA   AA   Not associated with any disorder
  rs1046319    8      c.2565A \> G   S855S                AG         AG                         AG   GG   GG   Diabetes mellitus, diabetes mellitus combined with deafness
